Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 18 Nov 2023
For the first time, fentanyl usage was monitored by the annual NSDUH survey, which found that 0.4% of Americans abused the drug in either prescription or illicitly produced forms.
Read Full NewsQurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes
1.
RFK Jr. Eyes Wireless, RF Radiation; Cancer by the Month; AI for Cancer Symptoms
2.
The FDA Approves the New Frontline Aggressive ALL Regimen.
3.
New Data Put ADCs on the Map in Relapsed SCLC
4.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
5.
The hidden costs of cancer for young survivors are derailing their financial futures
1.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
2.
Teaching Oncologic Emergencies Through Priority-Based Learning
3.
Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives
4.
Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
When Unexplained Bruising May Require Blood Testing
2.
Understanding the Importance of Follow-Up After Cancer Treatment
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
From Guidelines to Practice: Hematology
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge